Friedlander Martin
Department of Cell Biology, The Scripps Research Institute, and Division of Ophthalmology, Scripps Clinic, La Jolla, CA 92037, USA.
J Clin Invest. 2007 Mar;117(3):576-86. doi: 10.1172/JCI31030.
Most diseases that cause catastrophic loss of vision do so as a result of abnormal angiogenesis and wound healing, often in response to tissue ischemia or inflammation. Disruption of the highly ordered tissue architecture in the eye caused by vascular leakage, hemorrhage, and concomitant fibrosis can lead to mechanical disruption of the visual axis and/or biological malfunctioning. An increased understanding of inflammation, wound healing, and angiogenesis has led to the development of drugs effective in modulating these biological processes and, in certain circumstances, the preservation of vision. Unfortunately, such pharmacological interventions often are too little, too late, and progression of vision loss frequently occurs. The recent development of progenitor and/or stem cell technologies holds promise for the treatment of currently incurable ocular diseases.
大多数导致视力严重丧失的疾病都是异常血管生成和伤口愈合的结果,通常是对组织缺血或炎症的反应。由血管渗漏、出血和伴随的纤维化引起的眼部高度有序组织结构的破坏会导致视轴的机械性破坏和/或生物功能障碍。对炎症、伤口愈合和血管生成的深入了解促使了有效调节这些生物过程并在某些情况下保护视力的药物的研发。不幸的是,这种药物干预往往太少、太晚,视力丧失的进展经常发生。祖细胞和/或干细胞技术的最新发展为治疗目前无法治愈的眼部疾病带来了希望。